The increasing public health burden of melanoma warrants evaluation of quality-of-life outcomes and the instruments most commonly used to measure quality of life in patients with melanoma. A review of…
The Dermatology Life Quality Index (DLQI) is an easy and practical way of quantifying the impact of skin disease. The role of DLQI in treatment guidelines and its emergence as…
Skindex-29 and Skindex-16 are validated measures of the effects of skin diseases on patients’ quality of life. This article reviews the development of both versions of Skindex, discusses their measurement…
In this overview of preference-based measures, utilities and willingness to pay (WTP) are discussed as measures relevant to dermatology for capturing the burden of skin diseases. An overview is provided…
The concept of quality of life (QOL) is becoming increasingly important in medicine, particularly in dermatology where many cutaneous diseases have the potential to affect the quality rather than the length…
Improvement of health-related quality of life (HRQoL) is a major goal of dermatology. Identifying how the skin condition affects lives, quantifying this burden, and using this information to improve patients’…
The current melanoma staging system, as defined by the American Joint Committee on Cancer (AJCC), is the standard by which melanoma prognosis is determined. This article focuses on the components…
Melanoma is an important public health problem in the United States and worldwide. The incidence of melanoma continues to increase at a high rate and deaths from melanoma are also…
Detection of melanoma at an early stage is crucial to improving survival rates in melanoma. Accurate diagnosis by current techniques including dermatoscopy remains difficult, and new tools are needed to…
The next few years may show that when the novel therapeutics reviewed in this article are used in thoughtful combinations, a new standard of care for the treatment of advanced…
